OIA response: Funding data for Hylo-Fresh eye drops

Response to the total spent on sodium hyaluronate [Hyaluronic acid] eye drops (Hylo-Fresh) in the last financial year.

30 September 2020

Dear [name and contact details redacted]

REQUEST FOR INFORMATION

Thank you for your request dated 2 September 2020 under the Official Information Act 1982 (OIA) for information relating to sodium hyaluronate [Hyaluronic acid] eye drops (Hylo-Fresh).  You asked:

  • how much Pharmac has spent on Hylo Fresh in the last financial year
  • this was a sole supply product until 2016. Is this still the case?

The total units funded and total price applicable in the 2019/20 financial year is shown in the table below.

Chemical

Presentation

Brand name

Units funded (mg)

Total price (NZD)

Sodium hyaluronate [Hyaluronic acid]

Eye drops 1 mg per ml

Hylo-Fresh

520,870

1,145,914

Note: a confidential rebate applies to all community funded dispensings of Hylo-Fresh.

I can also confirm that the Sole Supply agreement for Hylo-Fresh ended 30 June 2016 and as such, we do not currently have a sole supply agreement for the supply of sodium hyaluronate [hyaluronic acid].

Please note that PHARMAC recently sought feedback on our draft 2020/21 Invitation to Tender (ITT) which includes sodium hyaluronate [hyaluronic acid]. View the consultation for more information about the draft ITT.

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely 

Rachel Read
Manager, Policy and Government Services